Leerink analyst Joseph Schwartz upgraded Fulcrum Therapeutics (FULC) to Outperform from Market Perform with a price target of $12, up from $4, ahead of the 12mg sickle-cell disease data. The firm is intrigued by the results so far, thinks the HbF increase is likely to improve with longer/higher dosing, and believes the stock has more room to run, especially with growing scarcity value in the SCD space. Leerink sees a positively skewed risk/reward heading into the data, with an up/down of +100%/-40%.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FULC:
- Cisco upgraded, CoreWeave downgraded: Wall Street’s top analyst calls
- Cantor upgrades Fulcrum to Overweight on sickle cell opportunity
- Fulcrum Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
- Oppenheimer biotech analyst holds an analyst/industry conference call
- Cautious Outlook for Fulcrum Therapeutics Amid Phase 1b Progress and Enrollment Uncertainties
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue